{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:46:00Z","timestamp":1792089960816,"version":"4.4.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00520-026-11301-w","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:11:00Z","timestamp":1791303060000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Febrile neutropenia in adults with diffuse large B-cell lymphoma receiving first-line R-CHOP-based therapy: a systematic review and meta-analysis of observational and trial evidence"],"prefix":"10.1007","volume":"34","author":[{"given":"Jamiel","family":"Reyes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"issue":"4","key":"11301_CR1","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Bri\u00e8re J, Herbrecht R, Tilly H, Bouabdallah R et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235\u2013242. https:\/\/doi.org\/10.1056\/NEJMoa011795","journal-title":"N Engl J Med"},{"issue":"18","key":"11301_CR2","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","volume":"23","author":"P Feugier","year":"2005","unstructured":"Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferm\u00e9 C et al (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulta. J Clin Oncol 23(18):4117\u20134126. https:\/\/doi.org\/10.1200\/JCO.2005.09.131","journal-title":"J Clin Oncol"},{"issue":"4","key":"11301_CR3","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trn\u011bn\u00fd M, Sharman JP et al (2022) Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 386(4):351\u2013363. https:\/\/doi.org\/10.1056\/NEJMoa2115304","journal-title":"N Engl J Med"},{"issue":"3","key":"11301_CR4","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00520-011-1306-6","volume":"20","author":"R Pettengell","year":"2012","unstructured":"Pettengell R, Johnsen HE, Lugtenburg PJ, Silvestre AS, D\u00fchrsen U, Rossi FG et al (2012) Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma. Support Care Cancer 20(3):647\u2013652. https:\/\/doi.org\/10.1007\/s00520-011-1306-6","journal-title":"Support Care Cancer"},{"issue":"9","key":"11301_CR5","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1200\/JCO-25-02938","volume":"44","author":"B Gyawali","year":"2026","unstructured":"Gyawali B, Bohlke K, Dickter JK, Kelkar AH, Knopf KB, Rapoport BL et al (2026) WBC growth factors: ASCO guideline update. J Clin Oncol 44(9):812\u2013824. https:\/\/doi.org\/10.1200\/JCO-25-02938","journal-title":"J Clin Oncol"},{"issue":"1","key":"11301_CR6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2010","unstructured":"Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N et al (2010) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1):8\u201332. https:\/\/doi.org\/10.1016\/j.ejca.2010.10.013","journal-title":"Eur J Cancer"},{"issue":"Suppl 5","key":"11301_CR7","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","volume":"27","author":"J Klastersky","year":"2016","unstructured":"Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M et al (2016) Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol 27(Suppl 5):v111\u2013v118. https:\/\/doi.org\/10.1093\/annonc\/mdw325","journal-title":"Ann Oncol"},{"key":"11301_CR8","unstructured":"National Comprehensive Cancer Network (2024) NCCN Clinical Practice Guidelines in Oncology: Hematopoietic Growth Factors. Version 2024. Plymouth Meeting (PA): NCCN.\u00a0 Available from: https:\/\/www.nccn.org\/guidelines. Accessed 2026"},{"issue":"10","key":"11301_CR9","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.annonc.2020.07.010","volume":"31","author":"G Curigliano","year":"2020","unstructured":"Curigliano G, Banerjee S, Cervantes A, Garassino MC, Garrido P, Girard N et al (2020) Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. Ann Oncol 31(10):1320\u20131335. https:\/\/doi.org\/10.1016\/j.annonc.2020.07.010","journal-title":"Ann Oncol"},{"issue":"11","key":"11301_CR10","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.3346\/jkms.2014.29.11.1493","volume":"29","author":"YW Choi","year":"2014","unstructured":"Choi YW, Jeong SH, Ahn MS, Lee HW, Kang SY, Choi JH et al (2014) Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP. J Korean Med Sci 29(11):1493\u20131500. https:\/\/doi.org\/10.3346\/jkms.2014.29.11.1493","journal-title":"J Korean Med Sci"},{"issue":"1","key":"11301_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-023-08250-z","volume":"32","author":"W Zheng","year":"2024","unstructured":"Zheng W, Chen Z, Zhu S, Cheng L, Hu Y, Yang Y et al (2024) Incidence and risk factors for febrile neutropenia of patients with diffuse large B-cell lymphoma receiving R-CHOP-21 in China. Support Care Cancer 32(1):43. https:\/\/doi.org\/10.1007\/s00520-023-08250-z","journal-title":"Support Care Cancer"},{"issue":"4","key":"11301_CR12","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.4143\/crt.2021.1168","volume":"54","author":"SH Jeong","year":"2022","unstructured":"Jeong SH, Kim SJ, Yoon DH, Park Y, Kang HJ, Koh Y et al (2022) Pegfilgrastim prophylaxis is effective in the prevention of febrile neutropenia and reduces mortality in patients aged \u226575 years with diffuse large B-cell lymphoma treated with R-CHOP: a prospective cohort study. Cancer Res Treat 54(4):1268\u20131277. https:\/\/doi.org\/10.4143\/crt.2021.1168","journal-title":"Cancer Res Treat"},{"issue":"7","key":"11301_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-025-09614-3","volume":"33","author":"SI Go","year":"2025","unstructured":"Go SI, Jeong EJ, Lee WJ, Park S, Park MJ, Lee GW (2025) Sarcopenia attenuates the efficacy of PEGylated granulocyte colony-stimulating factor in preventing febrile neutropenia. Support Care Cancer 33(7):533. https:\/\/doi.org\/10.1007\/s00520-025-09614-3","journal-title":"Support Care Cancer"},{"key":"11301_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2020) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"issue":"4","key":"11301_CR15","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1093\/cid\/cir073","volume":"52","author":"AG Freifeld","year":"2010","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA et al (2010) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52(4):e56\u2013e93. https:\/\/doi.org\/10.1093\/cid\/cir073","journal-title":"Clin Infect Dis"},{"issue":"7414","key":"11301_CR16","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557\u2013560. https:\/\/doi.org\/10.1136\/bmj.327.7414.557","journal-title":"BMJ"},{"issue":"4","key":"11301_CR17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G (2019) How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health 22(4):153\u2013160. https:\/\/doi.org\/10.1136\/ebmental-2019-300117","journal-title":"Evid Based Ment Health"},{"issue":"7","key":"11301_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010247","volume":"6","author":"J IntHout","year":"2016","unstructured":"IntHout J, Ioannidis JPA, Rovers MM, Goeman JJ (2016) Plea for routinely presenting prediction intervals in meta-analysis. BMJ Open 6(7):e010247. https:\/\/doi.org\/10.1136\/bmjopen-2015-010247","journal-title":"BMJ Open"},{"issue":"7109","key":"11301_CR19","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629\u2013634. https:\/\/doi.org\/10.1136\/bmj.315.7109.629","journal-title":"BMJ"},{"issue":"3","key":"11301_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W (2010) Conducting meta-analyses in R with the metafor package. J Stat Softw 36(3):1\u201348. https:\/\/doi.org\/10.18637\/jss.v036.i03","journal-title":"J Stat Softw"},{"key":"11301_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"11301_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JAC Sterne","year":"2016","unstructured":"Sterne JAC, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"BMJ"},{"issue":"4","key":"11301_CR23","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2478\/abm-2025-0021","volume":"19","author":"P Nakaphan","year":"2025","unstructured":"Nakaphan P, Uaprasert N (2025) Effects of primary granulocyte colony-stimulating factor (G-CSF) prophylaxis for chemotherapy-induced febrile neutropenia in diffuse large B-cell lymphoma patients receiving the R-CHOP-21 regimen. Asian Biomed (Res Rev News) 19(4):165\u2013173. https:\/\/doi.org\/10.2478\/abm-2025-0021","journal-title":"Asian Biomed (Res Rev News)"},{"issue":"1","key":"11301_CR24","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3390\/hematolrep16010008","volume":"16","author":"M Morimoto","year":"2024","unstructured":"Morimoto M, Yokoya Y, Yoshida K, Kosako H, Hori Y, Mushino T et al (2024) Predictive model for occurrence of febrile neutropenia after chemotherapy in patients with diffuse large B-cell lymphoma: a multicenter, retrospective, observational study. Hematol Rep 16(1):76\u201388. https:\/\/doi.org\/10.3390\/hematolrep16010008","journal-title":"Hematol Rep"},{"key":"11301_CR25","doi-asserted-by":"publisher","DOI":"10.1177\/11795549261423995","volume":"20","author":"LY Chen","year":"2026","unstructured":"Chen LY, Tsai CA, Liao PW, Teng LC, Lin CH, Su YC et al (2026) Risk factors for febrile neutropenia in patients with newly diagnosed diffuse large B-cell lymphoma undergoing initial R-CHOP treatment. Clin Med Insights Oncol 20:11795549261423995. https:\/\/doi.org\/10.1177\/11795549261423995","journal-title":"Clin Med Insights Oncol"},{"issue":"4","key":"11301_CR26","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.4143\/crt.2021.944","volume":"54","author":"DY Kim","year":"2022","unstructured":"Kim DY, Nam J, Chung JS, Jeon BE, Lee JH, Jo JC et al (2022) Predictive parameters of febrile neutropenia and clinical significance of G-CSF receptor signaling pathway in the development of neutropenia during R-CHOP chemotherapy with prophylactic pegfilgrastim in patients with diffuse large B-cell lymphoma. Cancer Res Treat 54(4):1256\u20131267. https:\/\/doi.org\/10.4143\/crt.2021.944","journal-title":"Cancer Res Treat"},{"issue":"6","key":"11301_CR27","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s12185-021-03118-6","volume":"113","author":"M Ise","year":"2021","unstructured":"Ise M, Matsuda K, Shimura A, Masamoto Y, Kurokawa M (2021) Primary prophylaxis with pegfilgrastim during the first cycle of R-CHOP to avoid reduction of dose intensity in elderly patients. Int J Hematol 113(6):823\u2013831. https:\/\/doi.org\/10.1007\/s12185-021-03118-6","journal-title":"Int J Hematol"},{"issue":"5","key":"11301_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71821","volume":"15","author":"J Wang","year":"2026","unstructured":"Wang J, Li H, Lin Q, Guo Y, Ma H, Xiang B et al (2026) Mecapegfilgrastim for prophylaxis of immunochemotherapy-induced neutropenia in patients with diffuse large B-cell lymphoma: a multicenter pilot trial. Cancer Med 15(5):e71821. https:\/\/doi.org\/10.1002\/cam4.71821","journal-title":"Cancer Med"},{"issue":"9880","key":"11301_CR29","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(13)60313-X","volume":"381","author":"D Cunningham","year":"2013","unstructured":"Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P et al (2013) Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 381(9880):1817\u20131826. https:\/\/doi.org\/10.1016\/S0140-6736(13)60313-X","journal-title":"Lancet"},{"issue":"8","key":"11301_CR30","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1080\/10428194.2016.1265111","volume":"58","author":"VA Morrison","year":"2017","unstructured":"Morrison VA, Weller EA, Habermann TM, Li S, Fisher RI, Cheson BD et al (2017) Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the Intergroup experience (CALGB 9793; ECOG-SWOG 4494). Leuk Lymphoma 58(8):1814\u20131822. https:\/\/doi.org\/10.1080\/10428194.2016.1265111","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"11301_CR31","first-page":"496","volume":"91","author":"E Brusamolino","year":"2006","unstructured":"Brusamolino E, Rusconi C, Montalbetti L, Gargantini L, Uziel L, Pinotti G et al (2006) Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica 91(4):496\u2013502 (PMID: 16537117)","journal-title":"Haematologica"},{"issue":"7","key":"11301_CR32","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00520-006-0201-z","volume":"15","author":"UJM Mey","year":"2007","unstructured":"Mey UJM, Maier A, Schmidt-Wolf IGH, Ziske C, Forstbauer H, Banat GA et al (2007) Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma. Support Care Cancer 15(7):877\u2013884. https:\/\/doi.org\/10.1007\/s00520-006-0201-z","journal-title":"Support Care Cancer"},{"issue":"3","key":"11301_CR33","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.critrevonc.2013.12.006","volume":"90","author":"GH Lyman","year":"2014","unstructured":"Lyman GH, Abella E, Pettengell R (2014) Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. Crit Rev Oncol Hematol 90(3):190\u2013199. https:\/\/doi.org\/10.1016\/j.critrevonc.2013.12.006","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"11301_CR34","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s00520-008-0430-4","volume":"16","author":"R Pettengell","year":"2008","unstructured":"Pettengell R, Schwenkglenks M, Leonard R, Bosly A, Paridaens R, Constenla M et al (2008) Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Support Care Cancer 16(11):1299\u20131309. https:\/\/doi.org\/10.1007\/s00520-008-0430-4","journal-title":"Support Care Cancer"},{"issue":"5","key":"11301_CR35","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.leukres.2012.02.002","volume":"36","author":"A Salar","year":"2012","unstructured":"Salar A, Haioun C, Rossi FG, D\u00fchrsen U, Pettengell R, Johnsen HE et al (2012) The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice. Leuk Res 36(5):548\u2013553. https:\/\/doi.org\/10.1016\/j.leukres.2012.02.002","journal-title":"Leuk Res"},{"issue":"28","key":"11301_CR36","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ et al (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 33(28):3199\u20133212. https:\/\/doi.org\/10.1200\/JCO.2015.62.3488","journal-title":"J Clin Oncol"},{"issue":"21","key":"11301_CR37","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","volume":"25","author":"NM Kuderer","year":"2007","unstructured":"Kuderer NM, Dale DC, Crawford J, Lyman GH (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25(21):3158\u20133167. https:\/\/doi.org\/10.1200\/JCO.2006.08.8823","journal-title":"J Clin Oncol"},{"issue":"10","key":"11301_CR38","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000029028","volume":"101","author":"Y Morita","year":"2022","unstructured":"Morita Y, Kanemasa Y, Sasaki Y, Ohigashi A, Tamura T, Nakamura S et al (2022) Impact of pegfilgrastim approval on relative dose intensity and outcomes of R-CHOP for diffuse large B-cell lymphoma. Medicine (Baltimore) 101(10):e29028. https:\/\/doi.org\/10.1097\/MD.0000000000029028","journal-title":"Medicine (Baltimore)"},{"issue":"14","key":"11301_CR39","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1200\/JCO.2013.51.6963","volume":"32","author":"G Bucaneve","year":"2014","unstructured":"Bucaneve G, Micozzi A, Picardi M, Ballanti S, Cascavilla N, Salutari P et al (2014) Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin\/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia. J Clin Oncol 32(14):1463\u20131471. https:\/\/doi.org\/10.1200\/JCO.2013.51.6963","journal-title":"J Clin Oncol"},{"issue":"9","key":"11301_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11091263","volume":"11","author":"N Coppola","year":"2022","unstructured":"Coppola N, Maraolo AE, Onorato L, Scotto R, Cal\u00f2 F, Atripaldi L et al (2022) Epidemiology, mechanisms of resistance and treatment algorithm for infections due to carbapenem-resistant Gram-negative bacteria: an expert panel opinion. Antibiotics (Basel) 11(9):1263. https:\/\/doi.org\/10.3390\/antibiotics11091263","journal-title":"Antibiotics (Basel)"},{"issue":"5","key":"11301_CR41","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/bjh.18348","volume":"198","author":"M Picardi","year":"2022","unstructured":"Picardi M, Giordano C, Pugliese N, Esposito M, Fatigati M, Muriano F et al (2022) Liposomal doxorubicin supercharge-containing front-line treatment in patients with advanced-stage diffuse large B-cell lymphoma or classical Hodgkin lymphoma: preliminary results of a single-centre phase II study. Br J Haematol 198(5):847\u2013860. https:\/\/doi.org\/10.1111\/bjh.18348","journal-title":"Br J Haematol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11301-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11301-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11301-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:47:48Z","timestamp":1792086468000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11301-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["11301"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-11301-w","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"16 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was not required because this study was based exclusively on previously published aggregate data and did not involve direct contact with human participants or access to identifiable personal data.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have read and agree to comply with the Springer Nature AI Policy. During preparation and revision, a large language model assistant (Claude, Anthropic) was used to support language editing, grammar and style refinement. The authors checked the applicable terms of use for the tool and confirm its suitability for publication-support use. The tool was not used to design the study, select studies, determine scientific conclusions, or generate references. All eligibility decisions, data extraction, and statistical analyses were specified and verified by the authors. The authors reviewed, edited, and verified all content, confirmed its originality and accuracy, and take full responsibility for the integrity of the manuscript, including the accuracy of references.","order":4,"name":"Ethics","label":"Generative artificial intelligence (AI) use","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The review was prospectively registered in PROSPERO (CRD420261368548). Three amendments to the registered protocol were made and the record has been updated: patient-level FN incidence replaced the registered comparative outcome as primary, with the comparative question retained as exploratory and the searches and eligibility criteria revised accordingly; two studies reporting R-CHOP-like regimens were retained, with a prespecified core R-CHOP sensitivity analysis excluding them; and stratification by study design was adopted at revision and is reported as an observation rather than a hypothesis test.","order":5,"name":"Ethics","label":"Registration and protocol","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1065"}}